Predictmedix Inc. Files Registration Statement on Form 20-F With the SEC
Predictmedix Inc. (OTCQB: PMEDF) has filed a registration statement on Form 20-F with the SEC, aiming to register its common shares. This step will enable the Company to operate as a reporting issuer under U.S. securities laws. Predictmedix focuses on developing AI technologies for health and safety, including real-time screening for COVID-19 symptoms, alcohol impairment, and mental health conditions. This move broadens its potential market presence in the U.S.
- Filing a registration statement with the SEC enables Predictmedix to operate as a reporting issuer in the U.S.
- Company develops disruptive AI technologies for health and safety, potentially expanding its market reach.
- No significant financial metrics or performance indicators provided.
TORONTO, June 18, 2021 (GLOBE NEWSWIRE) -- Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”), announced today that it has filed a registration statement on Form 20-F to register its common shares with the United States Securities and Exchange Commission (the “SEC”). Once the registration statement has been declared effective by the SEC, the Company will be a reporting issuer under the United States securities laws.
About Predictmedix Inc.
Predictmedix (CSE: PMED | OTCQB: PMEDF) is an AI (Artificial Intelligence) company developing disruptive technologies for the health and safety of people at work, in public environments, and by supporting healthcare systems with AI powered tools to facilitate better care and outcomes. Our AI powered screening products analyze real-time data from multispectral cameras and other sensors to detect when individuals may exhibiting symptoms of COVID-19 & other infectious diseases and also impairment due to alcohol & cannabis. We are also expanding our technology to screen for mental illnesses such as Alzheimer's, dementia, and depression. To learn more about our partnerships, where to buy our solutions, and company updates, visit Predictmedix.com.
Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."
Predictmedix Inc. trades as “PMED” on the Canadian Securities Exchange and “PMEDF” on the OTCQB market in the United States.
For more information, visit predictmedix.com
Or follow us on our social media platforms:
Twitter
Instagram
LinkedIn
Information that may be important to investors will be routinely posted on all these sites.
Investor Relations:
Ehsan Agahi, Investor Relations
Tel: (778) 229-4319
Email: IR@predictmedix.com
Caution Regarding Forward-Looking Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
FAQ
What is the significance of Predictmedix's registration statement filed with the SEC?
What technologies does Predictmedix develop?
What is the stock symbol for Predictmedix in the U.S.?
When did Predictmedix announce its SEC filing?
